MiNK Therapeutics (INKT)
10.71
+0.65 (6.46%)
Upcoming Events
Latest Headlines
MiNK Therapeutics (INKT) PT Raised to $50 at B.Riley
October 21, 2026 8:23 AM - StreetInsider
Form 4 MiNK Therapeutics, Inc. For: Oct 11 Filed by: Buell Jennifer
October 14, 2026 2:37 PM - SEC Filing
Form 144 MiNK Therapeutics, Inc. Filed by: Buell Jennifer
October 13, 2026 8:37 AM - SEC Filing
MiNK Therapeutics to Present Data on Treatment-Resistant Colorectal Cancer and Clearance of Senescent Tumor Cells and Fibroblasts at SITC 2026
October 2, 2026 9:00 AM - StreetInsider
MiNK Therapeutics joins ARPA-H's $87M room-temperature cell therapy program
September 30, 2026 7:58 AM - StreetInsider
MiNK Therapeutics Selected for ARPA-H-Funded Initiative to Advance Room-Temperature Cell Therapy
September 30, 2026 7:57 AM - Globe NewsWire
Form S-8 MiNK Therapeutics, Inc.
August 13, 2026 4:34 PM - SEC Filing
Form 10-Q MiNK Therapeutics, Inc. For: Jun 30
August 13, 2026 4:31 PM - SEC Filing
Form 8-K MiNK Therapeutics, Inc. For: Aug 13
August 13, 2026 7:41 AM - SEC Filing
MiNK Therapeutics reports Q2 2026 results and Phase 2 trial data
August 13, 2026 7:30 AM - StreetInsider
MiNK Therapeutics Reports Second Quarter 2026 Financial Results and Reports Observations from Randomized Phase 2 Trial of agenT-797 in Acute Lung Injury
August 13, 2026 7:30 AM - StreetInsider
MiNK Therapeutics to Report Second Quarter 2026 Financial Results, Provide Clinical Updates on agenT-797 in Lung Injury, and Highlight Important Business Updates
August 6, 2026 8:19 AM - Globe NewsWire
Agenus posts Q2 revenue of $34.5M, plans Phase 3 colon cancer trial
August 6, 2026 7:30 AM - StreetInsider
Agenus Reports Second Quarter 2026 Results and Advances Phase 3 ROBBIN Trial of BOT+BAL in Neoadjuvant MSS Colon Cancer
August 6, 2026 7:30 AM - BizWire
Full Article List
